FindTrial
Sign In

Study on the Effect of Safoof Maghz Tukhm Jamun (Syzygium cumini) in Managing Type-2 Diabetes

An Uncontrolled Open Label Clinical Trial of Safoof Maghz Tukhm Jamun ( Syzygium cumini) In The Management of Ziabetes Shakri (Diabetes Mellitus) Type-2 - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/086964
Enrollment
40
Registered
2025-05-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Safoof maghz tukhmn jamun: The test drug will be given orally 5 gram twice a day empty stomach Control Intervention1: NIL: NIL

Sponsors

Govt Tibbi College and Hospital Patna
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Fasting plasma glucose 126 to 150 mg per dl. 2. Post prandial plasma glucose 200 to 250 mg per dl. 3. HbA1C 6.5 to 8.0 percent. 4. Patients between 25 to 60 years of age. 5. Patient of either sex. 6. Patient willing to sign the written informed consent.

Exclusion criteria

Exclusion criteria: Patients of malnutrition with diabetes mellitus. Diagnosed complicated cases of Diabetes Mellitus diabetic ketoacidosis retinopathy neuropathy nephropathy coronary artery disease peripheral vascular disease cerebrovascular disease liver disease and hypertension. Known cases of Diabetes Mellitus more than 10 years Impaired organ functions. Pregnant and lactating women. Patient who fails to give consent. Mentally retarded and bed ridden patients. Patients having any type of malignancy.

Design outcomes

Primary

MeasureTime frame
the therapeutic efficacy and safety of safoof maghz tukhmn jamun in the management of Ziabetus Shakri (Diabetes Mellitus) Type-2.Timepoint: the therapeutic efficacy and safety of safoof maghz tukhmn jamun in the management of Ziabetus Shakri (Diabetes Mellitus) Type-2.—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Md Hafizur Rahman

Govt. Tibbi College and Hospital Kadamkuan Patna Bihar 800003

drmdnajibur.rahman@gmail.com9934959517

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026